Xencor (XNCR) Cash from Operations Growth (3y) (2016 - 2026)

Xencor (XNCR) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn - -5.07%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.90 Bn 61.14 Bn 3.31 Bn -7.60%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn -
9 Revolution Medicines 37.46 Bn 37.46 Bn - -
10 Xencor 1.50 Bn 1.12 Bn - -30.24%

Historic Data

Download Data
DateValue
Mar 31, 2026 -30.24%
Dec 31, 2025 -28.39%
Sep 30, 2025 -197.70%
Jun 30, 2025 -41.31%
Mar 31, 2025 -68.56%
Dec 31, 2024 -41.06%
Sep 30, 2024 10.32%
Jun 30, 2024 -91.08%
Mar 31, 2024 -23.80%
Dec 31, 2023 2.07%
Sep 30, 2023 -91.81%
Jun 30, 2023 -11.33%
Mar 31, 2023 -73.65%
Dec 31, 2022 -7.66%
Sep 30, 2022 43.50%
Jun 30, 2022 -25.98%
Mar 31, 2022 32.20%
Dec 31, 2021 78.44%
Sep 30, 2021 -55.84%
Jun 30, 2021 30.23%